Mizuho Initiates Coverage on GRAIL (NASDAQ:GRAL)

Mizuho assumed coverage on shares of GRAIL (NASDAQ:GRAL) in a note issued to investors on Friday, MarketBeat reports. The brokerage set a “neutral” rating and a $58.00 price target on the stock. Mizuho’s price objective would suggest a potential upside of 27.11% from the company’s previous close.

Several other equities analysts have also weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a research note on Thursday, January 22nd. Morgan Stanley cut their price target on GRAIL from $110.00 to $60.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 24th. Guggenheim cut their price target on GRAIL from $130.00 to $75.00 and set a “buy” rating for the company in a research note on Monday, March 30th. Robert W. Baird set a $82.00 price target on GRAIL in a research note on Friday, February 20th. Finally, Canaccord Genuity Group cut their price target on GRAIL from $105.00 to $80.00 and set a “buy” rating for the company in a research note on Friday, February 20th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $68.63.

GRAIL Stock Down 4.1%

Shares of GRAIL stock opened at $45.63 on Friday. GRAIL has a twelve month low of $22.30 and a twelve month high of $118.84. The business has a 50-day moving average price of $63.91 and a 200 day moving average price of $79.76. The firm has a market cap of $1.87 billion, a PE ratio of -4.08 and a beta of 4.62.

GRAIL (NASDAQ:GRAL) last announced its quarterly earnings results on Thursday, February 19th. The company reported ($2.44) earnings per share for the quarter, beating the consensus estimate of ($3.33) by $0.89. GRAIL had a negative return on equity of 17.11% and a negative net margin of 277.46%.The firm had revenue of $43.60 million during the quarter, compared to analyst estimates of $43.33 million. On average, sell-side analysts expect that GRAIL will post -15.15 EPS for the current year.

Insiders Place Their Bets

In other GRAIL news, CFO Aaron Freidin sold 45,806 shares of the business’s stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $49.92, for a total transaction of $2,286,635.52. Following the completion of the sale, the chief financial officer directly owned 260,669 shares in the company, valued at approximately $13,012,596.48. The trade was a 14.95% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, President Joshua J. Ofman sold 61,665 shares of the business’s stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $49.92, for a total value of $3,078,316.80. Following the sale, the president owned 371,216 shares of the company’s stock, valued at approximately $18,531,102.72. This trade represents a 14.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 310,267 shares of company stock worth $15,485,396. Corporate insiders own 1.85% of the company’s stock.

Institutional Investors Weigh In On GRAIL

Several large investors have recently bought and sold shares of GRAL. N.E.W. Advisory Services LLC purchased a new stake in GRAIL during the 4th quarter worth approximately $26,000. Comerica Bank increased its stake in GRAIL by 59.2% during the 3rd quarter. Comerica Bank now owns 465 shares of the company’s stock worth $27,000 after buying an additional 173 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in GRAIL during the 4th quarter worth approximately $28,000. Elyxium Wealth LLC purchased a new stake in GRAIL during the 4th quarter worth approximately $31,000. Finally, Intesa Sanpaolo S.p.A. purchased a new stake in GRAIL during the 4th quarter worth approximately $44,000.

Key Headlines Impacting GRAIL

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: Analyst consensus remains constructive: Street coverage still shows an average rating of “Moderate Buy” with a consensus price target around $72.83, implying meaningful upside from current levels. Article Title
• Neutral Sentiment: Mizuho initiated coverage with a “neutral” rating and a $58 price target (roughly mid‑teens to low‑20s % upside vs. current quoted levels); the call is cautious and reflects uncertainty rather than outright bullishness. Article Title
• Neutral Sentiment: Piper Sandler also initiated coverage with a “neutral” rating and a $54 price target, signaling analyst caution and limited near‑term conviction. Article Title
• Negative Sentiment: Reported study setback: coverage initiation notes reference a recent study disappointment that prompted the neutral stances — clinical execution and near‑term data risk are now front and center for investors. Article Title
• Negative Sentiment: Insider selling by senior management: CEO, President and CFO sold sizable blocks on April 8 (CEO ~123,502 shares; President ~61,665; CFO ~45,806), materially reducing their holdings — a strong negative signal to the market and a likely contributor to downward pressure. Article Title

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.